Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Former FDA chief scientist faults agency over COVID-19 antibody test ‘chaos’

June 10, 2020 By Chris Newmarker

Dr. Jesse Goodman Georgetown University FDA

Dr. Jesse Goodman, Georgetown University

FDA allowed both qualified and unqualified entities to flood the market with COVID-19 antibody tests, and the result was “chaos,” FDA’s former chief scientist Jesse Goodman told a U.S. House subcommittee.

A month after FDA tightened oversight of the tests and started withdrawing tests from the market, there is still enough concern about false results that the American Medical Association is recommending against people using the tests outside of certain settings, added Dr. Jesse Ehrenfeld, immediate past chair of the AMA’s board of trustees, speaking yesterday to the Subcommittee on Economic and Consumer Policy.

Rep. Raja Krishnamoorthi (D-Ill.), the subcommittee’s chair, faulted FDA for initially relying on self-validation from companies.

“FDA took companies at their word. When I ask my kids to clean their room, I can tell you my wife and I don’t rely on self-validation. However, that is the policy adopted by FDA until recently,” Krishnamoorthi said.

Goodman — who left FDA in 2014 to become the founding director of the Center on Medical Product Access, Safety and Stewardship (COMPASS) at Georgetown University — noted that FDA is now acting to correct the situation. Besides requiring serological test makers to submit for an emergency use authorization, the agency has also set up an independent performance validation study effort with the National Institutes of Health’s National Cancer Institute.

Experts testifying to the House subcommittee said FDA must quickly review unregulated tests and recall junk tests, with Goodman suggesting a prioritized review of “high risk” tests.

For now, the antibody tests’ main use should be for population-based prevalence tests, the experts told the panel.

AdvaMed’s AdvaMedDx division responded to the hearing by describing the serological tests as essential tools for clinicians and public health experts in maximizing diagnostic information to help prevent, detect and treat COVID-19.

“So far, more than a dozen commercial serology/antibody in vitro diagnostic tests have received EUAs. Diagnostic test manufacturers are delivering millions of these high-quality, highly sensitive and specific tests each month, and they are all validated to FDA’s exacting standards,” said Susan Van Meter, executive director of AdvaMedDx.

 

 

Related Articles Read More >

A photo of former FDA official Bakul Patel
Google Health hires FDA’s chief digital health officer
FDA
FDA moves forward with Voluntary Improvement Program to bolster medical device quality
Medtronic Hugo robot-assisted surgery system
The road to a robot: Medtronic’s development process for its Hugo RAS system
iRhythm stays silent on federal grand jury subpoenas

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech